1. Patients’ daily reporting of symptoms via mobile application reveals a significant difference between patients’ perceptions and doctors’ interpretationsCvetka Grašič-Kuhar, Nina Privšek, Marjetka Sraka, Ema Grašič, Timotej Kovač, Matjaž Kukar, 2025, original scientific article Abstract: Electronic patient-reported outcomes (ePROs) are gaining importance. The aim of this study was to investigate the difference in the reporting of symptoms between patients via mobile application (m-app) and doctor assessments. Additionally, usability and satisfaction with the use of the m-app were assessed. Methods: In this single-center prospective cohort study, we analyzed ePROs in 46 patients receiving (neo)adjuvant chemotherapy for early breast cancer. Patients recorded the occurrence and intensity of symptoms via the Android-based m-app daily. Three-monthly, patients completed validated quality of life questionnaires (EORTC C30 and BR23). For the 10 most common symptoms reported by patients, we compared the frequencies and grades between patients and doctors. Additionally, we compared daily symptom reports with questionnaire results. Finally, the usefulness of and level of satisfaction with the m-app by patients and doctors were evaluated. Results: During the study, patients recorded almost twice as many different symptoms through the m-app as doctors did in the electronic health records (75 vs 49). Symptoms were described by patients as mild (67%), moderate (30%), or severe (3%). The frequency and intensity of symptoms reported by patients were significantly higher than those reported by doctors (p<0.001). Fatigue, insomnia and dry mouth were the three main symptoms reported in more than 75% of patients, but insomnia and dry mouth were also the symptoms most often underreported by doctors. After three months of chemotherapy, QoL assessments revealed worsening of physical, social, cognitive and role functioning, increased fatigue, systemic therapy side effects, and dyspnea but a reduction in arm and shoulder problems. Patients and doctors rated the m-app with an overall score of 4.5 out of 5 (IQR 1.0). Patients expressed high levels of satisfaction with and usability of the m-app. In contrast, doctors were somewhat reluctant to perceive ePROs as an additional burden with patient management. Conclusion: This study revealed a significant discrepancy between patients’ daily symptom reports via the m-app and doctors’ assessments, indicating that healthcare professionals may not fully capture patients’ experiences. This underscores the importance of integrating PROs to accurately evaluate patients’ conditions. Our m-app serves as a promising tool for reporting and managing side effects during systemic treatment of breast cancer.
Keywords: breast cancer, mobile application, patients, doctors
Published in DiRROS: 05.12.2025; Views: 211; Downloads: 100
 Link to file |
2. Imunohistokemična analiza izražanja glukokortikoidnih receptorjev pri zgodnjem raku dojk in njihov vpliv na odgovor na zdravljenje z neoadjuvantno sistemsko terapijoMarjetka Sraka, Barbara Gazić, Primož Drev, Cvetka Grašič-Kuhar, 2024, original scientific article Abstract: Glukokortikoidni receptor (GR) je različno izražen na tumorskih in imunskih celicah raka dojk, njegova izraženost pa je morda odvisna od molekularnega podtipa raka dojk, prav tako njegova izraženost morda vpliva na odgovor na neoad-juvantno sistemsko terapijo. Naš namen je vpeljati zanesljivo imunohistokemično barvanje s protitelesi proti GR, drugi namen pa je oceniti izraženost GR na vzorcih raka dojk in preučiti, ali se ta izraža različno pri različnih podtipih in ali njegova izraženost vpliva na odgovor na neoadjuvantno sistemsko terapijo.
Keywords: rak dojk, neoadjuvantno sistemsko zdravljenje, glukokortikoidni receptor
Published in DiRROS: 26.07.2024; Views: 1143; Downloads: 568
 Full text (7,50 MB) |
3. |
4. Pogostnost in jakost simptomov med kemoterapijo : primerjava med poročanjem bolnic in zdravnikovNina Privšek, Tina Zupančič, Ema Grašič, Marjetka Sraka, Timotej Kovač, Matjaž Kukar, Cvetka Grašič-Kuhar, 2022, published professional conference contribution abstract Keywords: onkologija, rak dojke, kemoterapija
Published in DiRROS: 27.01.2023; Views: 1608; Downloads: 445
Full text (47,18 KB) |
5. Poročanje o neželenih učinkih med zdravljenjem s kemoterapijo : analiza raziskave OnkovedNina Privšek, Tina Zupančič, Ema Grašič, Marjetka Sraka, Klara Grad, Timotej Kovač, Matjaž Kukar, Cvetka Grašič-Kuhar, 2022, published scientific conference contribution Abstract: Zdravljenje s kemoterapijo je povezano s številnimi stranskimi učinki, ki so večinoma blagi in prehodne narave. Objektiviziramo jih glede na 5. izdajo skupnih terminoloških kriterijev za neželene učinke (angl. Common terminology criteria for adverse events; CTCAE). V zadnjih letih so v klinično uporabo vstopile tudi lestvice za bolnikovo poročanje neželenih učinkov (npr. PRO-CTCAE; angl. Patient reported outcomeCommon terminology criteria for adverse events). Raziskave, ki so do sedaj primerjale zdravnikova in bolnikova poročila o stranskih učinkih, so ugotovile, da zdravniki poročajo statistično značilno manj simptomov in nižje graduse kot bolniki. Nadalje je bilo ugotovljeno tudi, da tesnejši nadzor nad stranskimi učinki privede do hitrejše razrešitve težjih oblik le-teh. V pričujočem prispevku predstavljamo rezultate raziskave, ki smo jo izvedli na Onkološkem inštitutu Ljubljana za oceno stopnje pojavnosti ter razlik v beleženju stranskih učinkov s strani zdravnikov in bolnikov. V sklopu raziskave smo ocenjevali tudi kakovost življenja med zdravljenjem s kemoterapijo in doprinos uporabe mobilne aplikacije k učinkovitejšem obvladovanju stranskih učinkov v vsakdanji klinični praksi.
Keywords: neželeni učinki, bolniki, sistemsko zdravljenje
Published in DiRROS: 17.01.2023; Views: 1770; Downloads: 463
Full text (515,71 KB) |
